首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1812460

Capecitabine市場按適應症、強度、藥物類型、年齡層、分銷管道、最終用戶和地區分類

Capecitabine Market, By Indication, By Strength, By Drug Type, By Age Group, By Distribution Channel, By End User, By Geography

出版日期: 2025年08月19日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

Capecitabine市場規模預計在 2025 年達到 4.923 億美元，預計到 2032 年將達到 7.601 億美元，2025 年至 2032 年的複合年成長率為 6.4%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場價值	4.923億美元
效能數據	2020-2024	預測期	2025-2032
預測期間（2025-2032年）的複合年成長率：	6.40%	2032年預測	7.601億美元

Capecitabine的全球市場是腫瘤藥物領域的重要部分，主要是一種口服Fluoropyrimidines氨基甲酸酯，作為 5-Fluorouracil(5-FU) 的前驅藥物。

Capecitabine憑藉其獨特的腫瘤選擇性活化機制以及相比靜脈注射更高的患者依從性，已成為癌症治療方案中的核心治療藥物，尤其適用於結直腸癌、乳癌和胃癌。該藥物的創新設計使其能夠透過三步驟酶連鎖在腫瘤組織內優先轉化為活性代謝物，從而顯著增強療效，同時最大限度地降低全身毒性。

隨著個人化醫療和以患者為中心的治療方法在全球醫療保健體系中日益受到重視，Capecitabine口服給藥在便利性、生活品質和醫療資源最佳化方面具有顯著優勢。市場涵蓋多種劑型、劑量和聯合治療，涵蓋單藥治療和輔助性治療方案。受全球癌症發病率上升、新興市場癌症治療可近性不斷擴大以及新型組合策略持續研究的推動，Capecitabine市場不斷發展，成為全球不同醫療機構綜合癌症治療策略的重要組成部分。

市場動態

Capecitabine的全球市場受到多個強勁市場促進因素的支撐，這些因素鞏固了其在癌症治療中日益成長的重要性。首先，全球癌症發生率不斷上升，其中結直腸癌和乳癌是全球最常見的兩種惡性腫瘤，這導致對有效的口服化療方案的需求持續成長，因為口服給藥可以減少就診次數、改善生活品質並減輕醫療系統的負擔。

此外，老年人口不斷成長，他們更容易患癌症，而Capecitabine的毒性可控，使其適合無法耐受強化靜脈治療的老年患者，這些因素正在推動市場成長。然而，市場面臨重大限制，包括學名藥的出現，這大大降低了品牌製劑的定價壓力，可能會限制創新者的收益成長。

嚴重的副作用，例如手足症候群、胃腸道毒性和潛在的心臟毒性，可能導致治療中斷，從而限制市場滲透。此外，標靶治療、免疫療法和新型藥物輸送系統的出現，對Capecitabine等傳統化療藥物構成了競爭挑戰。儘管如此，仍存在著提高療效和拓寬治療適應症的重要機遇，特別是透過開發標靶治療療法和免疫調節劑的聯合治療。同時，基於藥物基因組學特徵的個人化給藥策略的持續研究，為在不斷發展的腫瘤學領域中拓展市場和改善患者預後提供了途徑。

本次調查的主要特點

本報告對全球Capecitabine市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了針對該市場的引人注目的投資提案。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
該報告根據公司亮點、產品系列、關鍵亮點、績效和策略等參數，概述了全球Capecitabine市場的主要企業。
人們相信，本報告中的見解可以幫助負責人和企業經營團隊就未來的產品發布、最新策略、市場擴張和行銷策略做出明智的決策。
全球Capecitabine市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球Capecitabine市場所使用的各種策略矩陣來更輕鬆地做出決策。

Hoffmann-La Roche Ltd（Roche）
Teva Pharmaceutical Industries Ltd
Mylan NV（Viatris Inc）
Cipla Ltd
Reddy's Laboratories Ltd
Sun Pharmaceutical Industries Ltd
Accord Healthcare Ltd
Fresenius Kabi AG
Hetero Labs Ltd
Natco Pharma Ltd
Apotex Inc
Sandoz（Novartis AG）
Intas Pharmaceuticals Ltd
Zydus Lifesciences Ltd
Glenmark Pharmaceuticals Ltd

第12章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第13章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI8442

Capecitabine Market is estimated to be valued at USD 492.3 Mn in 2025 and is expected to reach USD 760.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 492.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.40%	2032 Value Projection:	USD 760.1 Mn

The global capecitabine market represents a critical segment within the oncology pharmaceutical landscape, centered around an oral fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU).

Capecitabine has established itself as a cornerstone therapeutic agent in cancer treatment protocols, particularly for colorectal, breast, and gastric cancers, owing to its unique tumor-selective activation mechanism and improved patient compliance compared to intravenous alternatives. The drug's innovative design allows for preferential conversion to its active metabolite within tumor tissues through a three-step enzymatic cascade, significantly enhancing therapeutic efficacy while minimizing systemic toxicity.

As healthcare systems worldwide increasingly prioritize personalized medicine and patient-centric treatment approaches, capecitabine's oral administration route offers substantial advantages in terms of convenience, quality of life, and healthcare resource optimization. The market encompasses various formulations, dosage strengths, and combination therapies, serving both monotherapy and adjuvant treatment protocols. With rising global cancer incidence rates, expanding access to oncology care in emerging markets, and continuous research into novel combination strategies, the capecitabine market continues to evolve as a vital component of comprehensive cancer care strategies across diverse healthcare settings worldwide.

Market Dynamics

The global capecitabine market is propelled by several compelling drivers that underscore its growing significance in oncology therapeutics. The primary driver stems from the escalating global cancer burden, with colorectal and breast cancers representing two of the most prevalent malignancies worldwide, creating sustained demand for effective oral chemotherapy options. The drug's superior patient compliance profile compared to intravenous chemotherapy regimens drives adoption, as oral administration reduces hospital visits, improves quality of life, and decreases healthcare system burden.

Additionally, the expanding geriatric population, which exhibits higher cancer susceptibility, fuels market growth as capecitabine's manageable toxicity profile makes it suitable for elderly patients who may not tolerate intensive intravenous therapies. However, the market faces significant restraints including the availability of generic versions that have substantially reduced pricing pressures on branded formulations, potentially limiting revenue growth for innovator companies.

Severe side effects such as hand-foot syndrome, gastrointestinal toxicity, and potential cardiotoxicity can lead to treatment discontinuation, restricting market penetration. Furthermore, the emergence of targeted therapies, immunotherapies, and novel drug delivery systems poses competitive challenges to traditional chemotherapy agents like capecitabine. Nevertheless, substantial opportunities exist through combination therapy development, particularly with targeted agents and immunomodulators, which can enhance therapeutic efficacy and expand treatment indications. Growing healthcare infrastructure in emerging markets presents untapped potential, while ongoing research into personalized dosing strategies based on pharmacogenomic profiles offers avenues for market expansion and improved patient outcomes in the evolving oncology landscape.

Key Features of the Study

This report provides in-depth analysis of the global capecitabine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global capecitabine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Hoffmann-La Roche Ltd (Roche), Teva Pharmaceutical Industries Ltd, Mylan N.V (Viatris Inc), Cipla Ltd, Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Accord Healthcare Ltd, Fresenius Kabi AG, Hetero Labs Ltd, Natco Pharma Ltd, Apotex Inc, Sandoz (Novartis AG), Intas Pharmaceuticals Ltd, Zydus Lifesciences Ltd, and Glenmark Pharmaceuticals Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global capecitabine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global capecitabine market

Market Segmentation

Indication Insights (Revenue, USD Mn, 2020 - 2032)
- Colorectal Cancer
- Breast Cancer
- Gastric Cancer
- Pancreatic Cancer
Strength Insights (Revenue, USD Mn, 2020 - 2032)
- 150 mg
- 500 mg
Drug Type Insights (Revenue, USD Mn, 2020 - 2032)
- Generic
- Branded
Age Group Insights (Revenue, USD Mn, 2020 - 2032)
- Adult
- Geriatric
Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End User Insights (Revenue, USD Mn, 2020 - 2032)
- Hospitals
- Specialty Centers
- Cancer Treatment Centers
- Homecare Settings
- Others (Academic and Research Institutes)
Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Hoffmann-La Roche Ltd (Roche)
- Teva Pharmaceutical Industries Ltd
- Mylan N.V (Viatris Inc)
- Cipla Ltd
- Reddy's Laboratories Ltd
- Sun Pharmaceutical Industries Ltd
- Accord Healthcare Ltd
- Fresenius Kabi AG
- Hetero Labs Ltd
- Natco Pharma Ltd
- Apotex Inc
- Sandoz (Novartis AG)
- Intas Pharmaceuticals Ltd
- Zydus Lifesciences Ltd
- Glenmark Pharmaceuticals Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Capecitabine Market, By Indication
- Global Capecitabine Market, By Strength
- Global Capecitabine Market, By Drug Type
- Global Capecitabine Market, By Age Group
- Global Capecitabine Market, By Distribution Channel
- Global Capecitabine Market, By End User
- Global Capecitabine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Capecitabine Market, By Indication, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Gastric Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Pancreatic Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Capecitabine Market, By Strength, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
150 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
500 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Capecitabine Market, By Drug Type, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Capecitabine Market, By Age Group, 2025-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Capecitabine Market, By Distribution Channel, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Capecitabine Market, By End User, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Specialty Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Others (Academic and Research Institutes)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

10. Global Capecitabine Market, By Region, 2020 - 2032, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

11. Competitive Landscape

Hoffmann-La Roche Ltd (Roche)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Mylan N.V (Viatris Inc)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Accord Healthcare Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Fresenius Kabi AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hetero Labs Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Natco Pharma Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Apotex Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sandoz (Novartis AG)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Intas Pharmaceuticals Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zydus Lifesciences Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Glenmark Pharmaceuticals Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies